Study identifier:NIS-CHU-DUM-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using effective Statins (CORVUS)
cardiovascular risk
-
No
-
All
1500
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.
Location
Location
Baja, Hungary
Location
Budapest III District, Hungary
Location
Budapest, Hungary
Location
Bekescsaba, Hungary
Location
Cegled, Hungary
Location
Debrecen, Hungary
Location
Gyula, Hungary
Location
Gyongyos, Hungary
Arms | Assigned Interventions |
---|---|
Patients at high cardiovascular risk | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.